Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Gastrointestinal 1

Conditions

Lymphoma 2Pancreatic Neoplasms 1Neoplasms 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma, T-Cell 1Lymphoma, B-Cell 1Leukemia, Myeloid, Acute 1Leukemia 1

Interventions

pembrolizumab 6Gemcitabine 6Taxes 3Nivolumab 3Cyclophosphamide 3Capecitabine 3Albumin-Bound Paclitaxel 3trametinib 2ruxolitinib 2pertuzumab 2palbociclib 2olaparib 2fludarabine 2entrectinib 2entinostat 2dabrafenib 2copanlisib 2abiraterone 2Vorinostat 2Sunitinib 2Specimen Handling 2Sirolimus 2Paclitaxel 2Leucovorin 2Ipilimumab 2Immunoglobulin G 2HhAntag691 2Fluorouracil 2Drug Therapy 2Doxorubicin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pancreatic Neoplasms × molibresib × Lymphoid × Clear all
NCT03925428 2020-09-28

Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and Lymphomas

National Cancer Institute (NCI)

Phase 1 Withdrawn
GastrointestinalLymphoid

Lymphoma, Pancreatic Neoplasms, Lymphoma, B-Cell, Lymphoma, T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡